CEACAM5 and neoplasm: The Immunoscore® (total tumour-infiltrating T-cell counts and cytotoxic tumour-infiltrating T-cells counts) has been validated in the study of Pagès et al., including 2681 patients with stage I–III CRC from 13 countries, with high Immunoscore® (27%) associated with MSI tumors and the lowest risk of recurrence at 5 years (p < 0.0001), independently of prognostic factors (apart from carcinoembryonic antigen (CEA) level and RAS/BRAF mutational status) [77].